Interview with Christian Schilling, CEO, Boehringer Ingelheim Austria
Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first…
Address: ‘Dr.-Boehringer-Gasse 5-11
A-1121 Wien’
,Austria
Tel: (+43 1) 80 105-0
Web: http://www.boehringer-ingelheim.at/
Boehringer Ingelheim – one of the world‘s 20 leading pharmaceutical companies
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
For more information please visit www.boehringer-ingelheim.com
Boehringer Ingelheim in Austria
Boehringer Ingelheim founded its first subsidiary outside Germany in a Viennese pharmacy in 1948. From these modest beginnings, the Austrian company has developed into a modern high technology concern.
Today the company is of great importance as a cancer research centre and one of the three biopharmaceutical research, development and production centres in the international group. As the Regional Center Vienna it is responsible for the pharmaceutical business (human pharmaceuticals and animal health) and for clinical trials in more than 30 countries in Central and Eastern Europe (including Austria).
Over the last years Boehringer Ingelheim has created 530 new jobs in Vienna and invested around 360 million euros in the Vienna site.
Activities of the Boehringer Ingelheim Regional Center Vienna
• Business responsiblity for Boehringer Ingelheim products in more than 30 countries of Central and Eastern Europa – Human Pharmaceuticals and Animal Health
• International Oncology Research Center
• Clinical Research in all therapeutic areas of the Corporation in Central and Eastern Europe (including Austria and Switzerland), Turkey, South Africa and Israel
• Biopharmaceutical research, development and production
Boehringer Ingelheim Regional Center Vienna
The Regional Center Vienna (RCV) is responsible for the human pharmaceuticals (prescription medicines and over-the-counter products) and animal health business in more than 30 Central and Eastern European countries. Moreover the whole clinical research of the region is managed by the RCV. Vienna is the oncology research center and a center of biopharmaceutical research, development and production in the international group of companies. Boehringer Ingelheim is also engaged in basic research, represented by the Research Institute of Molecular Pathology (IMP) in Vienna. Therefore BI is one of the most research focused pharmaceutical companies in Austria. In 2011 the Boehringer Ingelheim Regional Center Vienna earned 736,2 million euros and had about 3,000 employees in Austria and Eastern Europe.
Animal Health
International Research Center of Oncology
Clinical research in all therapeutic areas of the business association – studies in 15 countries of Central and Eastern Europe (including Austria)
Biopharmaceutical development and manufacturing of pharmaceuticals
Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first…
Michael Krebs, managing director of the Institute of Molecular Biotechnology (IMBA), the leading publicly funded non-university biomedical research organization in Austria, provides an overview of IMBA’s role in the Austrian…
Christina Nageler, managing director of the Austrian Self Care Association (IGEPHA), the representative voice of the Austrian OTC community, provides an insight into the obstacles associated with the sale of…
Wolfgang Jank, general manager and founder, and Tina Theuer, managing partner, of first pharma J.M.T. GmbH, a young Austrian pharmaceutical service company, discuss the challenges of founding a new business…
Philipp von Lattorff, country managing director of Boehringer Ingelheim’s Regional Centre Vienna (RCV) discusses the current mandate of the center and the dynamic performance of its 33 members, as well…
Prof. Johannes Khinast, CEO and scientific director, and Dr. Thomas Klein, CEO and business director of the Research Center Pharmaceutical Engineering, or RCPE, the world’s first pharmaceutical engineering company that…
Dr. Andrea Podczeck-Schweighhofer, president of the Austrian Society of Cardiology, the representative voice of the Austrian cardiology ecosystem, provides an overview into the challenges associated with research in Austria and…
Sylvia Hofinger, director general of the Association of the chemical industry of Austria (FCIO), the representing voice of the Austrian chemical industry, discusses the drug pricing regulations that are affecting…
Karsten Schlemm MD, CEO of Merz Pharma Austria, a leading international German based aesthetic company, provides an in-depth look into the company´s transformation from pharmaceuticals to the aesthetics sector as…
Manuel Reiberg, president of the Forum of the Research-Based Pharmaceutical Industry in Austria (FOPI), which represents the 27 leading pharmaceutical innovators in Austria focused on pharmaceutical innovation, discusses the struggles…
Herwig Ostermann, executive director of the Austrian Public Health Institute (GOeG), a neutral entity that brings expertise and evidence together to help plan and promote Austrian healthcare, provides insights into…
Dr. Erwin Klein, CEO and co-founder of easypharm, a generics and OTC company founded by Austrians for Austria, provides an overview of his exciting entrepreneurial experience and the challenges associated…
Ana Kostova, Austrian country president for AstraZeneca, a global powerhouse in innovative drugs and R&D, discusses the opportunities and challenges of introducing innovative treatments into the Austrian healthcare system as…
See our Cookie Privacy Policy Here